Literature DB >> 6848378

The role of myosin light chain phosphorylation in regulation of the cross-bridge cycle.

R A Murphy, M O Aksoy, P F Dillon, W T Gerthoffer, K E Kamm.   

Abstract

Ca2+ binding to myofibrillar regulatory sites can produce conformational changes allowing cross-bridge attachment and cycling. Measurements of smooth muscle actomyosin ATPase activity suggested that Ca2+ might act indirectly to mediate cross-bridge attachment by stimulating myosin light chain phosphorylation. However, the predicted obligatory relationship between developed force and myosin phosphorylation was not always observed in living smooth muscle. The observation that myosin phosphorylation was always tightly correlated with average cross-bridge cycling rates estimated from isotonic shortening velocities suggested that Ca2+ has two regulatory roles. One action is exerted via a Ca2+-binding protein whose identity is unknown in smooth muscle. This regulatory site acts like other Ca2+-binding regulatory proteins in muscle to permit cross-bridge interaction and to determine active stress. The second regulatory role involves stimulation of myosin light chain kinase and light chain phosphorylation. Increasing the level of phosphorylated cross-bridges increases shortening velocities or rate of force development. We suggest that the dephosphorylated cross-bridges are noncycling or slowly cycling in activated smooth muscle. Smooth muscle may be a particularly favorable experimental preparation for demonstrating a general regulatory role of myosin phosphorylation in modulating the kinetics and energetics of muscle contraction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848378

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  14 in total

1.  Intracellular calcium levels in canine basilar artery smooth muscle following experimental subarachnoid hemorrhage: an electron microscopic cytochemical study.

Authors:  K Kohno; S Sakaki; S Ohue; Y Kumon; K Matsuoka
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

2.  Contraction of vascular smooth muscle induced by phorbol 12,13 dibutyrate in human and rat pulmonary arteries.

Authors:  J P Savineau; R Marthan; H Crevel
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

3.  Influence of pH on isometric force development and relaxation in skinned vascular smooth muscle.

Authors:  J P Gardner; F P Diecke
Journal:  Pflugers Arch       Date:  1988-08       Impact factor: 3.657

4.  A myosin phosphatase modulates contractility in skinned smooth muscle.

Authors:  C Bialojan; J C Rüegg; J DiSalvo
Journal:  Pflugers Arch       Date:  1987-10       Impact factor: 3.657

5.  Myoplasmic [ca], crossbridge phosphorylation and latch in rabbit bladder smooth muscle.

Authors:  Young-Don Kim; Min-Hyung Cho; Seong-Chun Kwon
Journal:  Korean J Physiol Pharmacol       Date:  2011-06-30       Impact factor: 2.016

6.  Excitation of vascular muscles by norepinephrine.

Authors:  K Hermsmeyer
Journal:  Ann Biomed Eng       Date:  1983       Impact factor: 3.934

7.  Ca2+ can affect Vmax without changes in myosin light chain phosphorylation in smooth muscle.

Authors:  M J Siegman; T M Butler; S U Mooers; A Michalek
Journal:  Pflugers Arch       Date:  1984-08       Impact factor: 3.657

8.  A strategy for selective anti-cancer drug concentration increase in rat glioma tissue with Ca(2+)-channel blocker co-administration: calcium kinetics in intra-glioma arteriolar smooth muscle cells.

Authors:  K Zenke; K Nakagawa; Y Kumon; S Ohta; T Hatakeyama; S Sakaki
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

9.  Free-calcium and force transients during depolarization and pharmacomechanical coupling in guinea-pig smooth muscle.

Authors:  B Himpens; A P Somlyo
Journal:  J Physiol       Date:  1988-01       Impact factor: 5.182

10.  The effect of Nicorandil on chronic cerebral vasospasm.

Authors:  T Matsui; T Nagafuji; K Tsutsumi; H Uchida; T Miyauchi; T Asano
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.